Novan, Inc., a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company's product candidates also include SB206, SB208, and SB414, which are targeted toward the treatment of either a specific microorganism or inflammatory components of disease pathology. Novan, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
http://www.priceseries.com/trade/NOVN-Novan-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019053020190610.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments